Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Kevin J Harrington"'
Autor:
F. Stephen Hodi, Kevin J. Harrington, Archie N. Tse, David C. Madoff, Jason J. Luke, Andrea Marie Perrone, Lawrence H. Schwartz, Anuradha D. Khilnani, Robert H.I. Andtbacka, Aurélien Marabelle, Gregory V. Goldmacher
Publikováno v:
Journal of Clinical Oncology
3141 Background: The approval of intratumoral (IT) immunotherapy for metastatic melanoma and the active development of numerous novel IT drugs have created a need for standardized evaluation of response to this unique treatment strategy. The Response
Autor:
Ramona F. Swaby, Barbara Burtness, Lisa Licitra, Makoto Tahara, Jean-Pascal Machiels, Ezra E.W. Cohen, Danny Rischin, Lillian L. Siu, Cecilia Pinheiro, Kevin J. Harrington, Ying Zhu, Chooi Peng Lee
Publikováno v:
Journal of Clinical Oncology. 38:TPS6589-TPS6589
TPS6589 Background: The PD-1 inhibitor pembrolizumab is currently approved as first-line monotherapy for patients with R/M HNSCC whose tumors express PD-L1 combined positive score (CPS) ≥1. In a phase 1b/2 trial (NCT02501096) of pembrolizumab plus
Autor:
Neus Baste, Prakash Neupane, Richard Greil, Tamara Rordorf, Thorsten Fuereder, Ricard Mesia, Barbara Burtness, Åse Bratland, Gilberto de Castro, Burak Gumuscu, Kevin J. Harrington, Makoto Tahara, Wan Zamaniah Wan Ishak, Brett G.M. Hughes, Ramona F. Swaby, Nuttapong Ngamphaiboon, Danny Rischin, Denis Soulières, Amanda Psyrri, Yayan Zhang
Publikováno v:
Journal of Clinical Oncology. 38:6505-6505
6505 Background: 1L P vs E improved OS in PD-L1 CPS ≥20 and CPS ≥1 populations, and led to noninferior OS in the total population, with favorable safety; 1L P+C vs E had superior OS in CPS ≥20, CPS ≥1, and total populations with comparable sa
Autor:
Joseph Elassal, Anna C. Pavlick, Adel Samson, Kevin J. Harrington, Jiaxin Niu, Francesca Aroldi, Robert S. Coffin, Alex Deterding, Scott Baum, Tawnya L. Bowles, Brendan D. Curti, Douglas Earl Laux, Mohammed M. Milhem, Joseph J. Sacco, Anna Olsson-Brown, Jason Chesney, Praveen K. Bommareddy, Mark R. Middleton, Ari M. Vanderwalde, Terence Duane Rhodes
Publikováno v:
Journal of Clinical Oncology. 38:e22050-e22050
e22050 Background: RP1 is an oncolytic HSV that encodes a fusogenic GALV-GP R- protein and GM-CSF. RP1 demonstrated tolerable safety and tumor regression alone and with nivolumab (nivo) in ph 1 in patients (pts) with a number of tumor types. To furth
Autor:
Ranee Mehra, Denis Soulières, Jonathan D. Cheng, José Dinis, Ezra E.W. Cohen, Barbara Burtness, Christophe Le Tourneau, Jianxin Lin, Nicolas Mach, Jean-Pascal Machiels, Ainara Soria, Kevin J. Harrington, Ramona F. Swaby, Lisa Licitra, Myung-Ju Ahn
Publikováno v:
Journal of Clinical Oncology. 37:6026-6026
6026 Background: The open-label, randomized, phase 3 KEYNOTE-040 study (NCT02252042) showed that pembro vs standard of care (SOC) chemotherapy prolonged survival in patients (pts) with recurrent and/or metastatic HNSCC whose disease progressed during
Autor:
Kevin J. Harrington, Mohammed M. Milhem, Merrick I. Ross, Igor Puzanov, Jason Chesney, Frances A. Collichio, Sanjiv S. Agarwala, Mark R. Middleton, Sumita Bhatta, Thomas Amatruda, Min Yi
Publikováno v:
Journal of Clinical Oncology. 37:9524-9524
9524 Background: T-VEC is a modified oncolytic herpes virus designed as an intralesional therapy for unresectable advanced melanoma. OPTiM was a randomized, phase 3 trial that showed improved durable response rate (DRR) with T-VEC vs GM-CSF in pts wi
Autor:
Wan Zamaniah Wan Ishak, Brett G.M. Hughes, Barbara Burtness, Denis Soulières, Richard Greil, Thorsten Fuereder, Amanda Psyrri, Nuttapong Ngamphaiboon, Burak Gumuscu, Kevin J. Harrington, Danny Rischin, Prakash Neupane, Yayan Zhang, Gilberto de Castro, Fan Jin, Tamara Rordorf, Makoto Tahara, Neus Baste, Ricard Mesia, Åse Bratland
Publikováno v:
Journal of Clinical Oncology. 37:6000-6000
6000 Background: KEYNOTE-048 is a phase 3 study of P or P + chemo (C) vs EXTREME (E) as 1L therapy for R/M HNSCC (NCT02358031). At the second interim analysis (IA2), P significantly improved OS in the PD-L1 combined positive score (CPS) ≥20 and ≥
Autor:
Tamara Rordorf, Anthony Hee Kong, Jason Chesney, Jenny J. Kim, Jesus Corral Jaime, Vittoria Espeli, Burak Gumuscu, Kevin J. Harrington, Nicolas Mach, Sheryl Treichel
Publikováno v:
Journal of Clinical Oncology. 36:6036-6036
6036Background: We evaluated the safety and efficacy of the combo of T-VEC, the first FDA-approved oncolytic immunotherapy that enhances systemic antitumor immune responses, and Pembro, an immune c...
Autor:
Kenji Hirotani, Martin Forster, Shuquan Chen, Christophe Le Tourneau, Jonathan Greenberg, Jose Ariza, Éva Remenár, Kevin J. Harrington
Publikováno v:
Journal of Clinical Oncology. 36:6045-6045
6045Background: P, a fully human monoclonal antibody can block HER3 activation. HER3 activation is a resistance mechanism to C, induced by the ligand heregulin (HRG). This randomized phase 2 study ...
Autor:
Kevin J. Harrington, Vijayvel Jayaprakash, Li Li, Peter Brossart, Mark Lynch, Robert L. Ferris, Naomi Kiyota, George R. Blumenschein, Jérôme Fayette, Joël Guigay, Maura L. Gillison, Nabil F. Saba, Lisa Licitra
Publikováno v:
Journal of Clinical Oncology. 36:6028-6028
6028Background: Nivo is the only immunotherapy to significantly improve overall survival (OS) in pts with platinum (plt)–refractory R/M SCCHN. In the randomized, open-label, phase 3 CheckMate 141 t...